Introduction
Krukenberg tumours (KTs) are histologically defined as carcinoma within the ovary containing mucin-filled signet ring cells and represent metastasis to the ovary. Up to 30 per cent of ovarian metastases arise from a colorectal origin, with gastric adenocarcinoma being the most common primary malignancy [1] . Colorectal KTs are an uncommon entity, comprising less than 10 per cent of all colorectal metastases. Here we present the management of a patient with symptomatic, metachronous KT. This case report has been reported in line with the SCARE criteria [2] . chemotherapy (FOLFOX for five cycles) upon which the patient travelled to Melbourne, Australia to seek alternative therapy. MRI and Whole Body FDG PET performed six months following diagnosis of recurrence demonstrated disease progression. MRI findings were of a 23 cm multiloculated mucinous appearing mass with enhancing internal septations, nodularity and diffusion restriction, as well as peritoneal nodularity in the right paracolic gutter and upper abdomen. On PET, there was patchy increase in FDG activity around the margins of the mass, as well as a separate 27 mm intensely FDG-avid mass between the mass and the right abdominal wall. Ultrasound-guided core biopsy of the mass confirmed metastatic mucinous adenocarcinoma with immunohistochemistry favouring a colonic primary ( Figs. 1 and 2) . Clinically, the patient was symptomatic with abdominal discomfort from her pelvic mass but no symptoms of bowel obstruction. The patient was discussed at a multidisciplinary meeting and the decision was made to undertake surgical excision. At laparotomy, the large tumour was dissected free from the small bowel and omentum and resected en bloc with the right fallopian tubes. There was also macroscopic right anterior abdominal wall and paracolic gutter recurrence which was excised, and a prophylactic left salpingo-oophorectomy performed. The patient recovered well with no post-operative complications. Histopathology confirmed moderately differentiated adenocarcinoma within the right ovary weighing 2630 g and measuring 230 × 210 × 200 mm in size, with immunostains confirming col- orectal origin. There was no evidence of malignancy in the left ovary and fallopian tube. The peritoneal nodules on the anterior abdominal wall and right paracolic gutter specimens had similar appearance to the ovarian tumour microscopically with clear resection margins. At six month follow-up her pre-operative symptoms had resolved, with no evidence of local or systemic recurrence (Fig. 3 ).
Presentation of case

Discussion
The name 'Krukenberg tumour' originates from Friedrich Ernst Krukenberg, a German physician who described five cases in 1896. The exact route of spread from the primary site to the ovary is unknown, with proposed theories describing haematogenous, lymphatic or trans-coloemic routes. Evidence for transc-coloemic spread is the high incidence of bilateral involvement as well as concomitant carcinomatosis peritoneii in KT; in one case series 18 out of 24 patients had documented peritoneal disease at the time of diagnosis [3] . Furthermore, the ovary has been suggested to be a sanctuary organ for systemic chemotherapy owing to the poor response of KTs to 5-FU based chemotherapy and even oxaliplatinor irinotecan-containing chemotherapy compared to extra-ovarian metastases, in part due to their voluminous, cystic and mucin-rich features [4, 5] .
KTs from colorectal origin are an overall indicator of poor prognosis, with median survival times reported between 19 to 29 months [1, 3, 6] and 5-year survival rates of 9% for synchronous KT and 20% for metachronous KT [7] . The data regarding long-term outcomes for KT from colorectal primaries lies mainly in small case series due to the limited incidence of this disease. Isolated metastatic disease to the ovaries has been shown to confer a significant overall survival advantage, with one series reporting mean overall survival time of 61 months with isolated ovarian disease treated with cytoreductive surgery. Other favourable prognostic indicators include postmenopausal status and unilateral ovarian involvement [6] .
Cytoreductive surgery (CRS) for KTs carries a significant locoregional or metastatic recurrence rate despite achieving an initial R0 resection. KTs in particular have been linked to retroperitoneal lymph node recurrence [8] . It has been suggested that should KT be discovered incidentally upon resection of a colorectal primary, systematic second-look surgery should be performed to exclude peritoneal metastasis [9] . Although prospective studies to directly investigate the role of CRS are lacking, there is evidence that maximal cytoreduction still does confer a survival benefit in selected patients. In one study of colorectal KTs, patients undergoing optimal cytoreduction (residual <1 cm) had a significantly longer median progression-free survival compared to those undergoing suboptimal cytoreduction (11 vs 2.5 months) and overall survival (35 vs 7 months), albeit with a high peri-operative mortality rate of 5% [10] . In another retrospective series, ovary-specific survival (date from KT diagnosis to death) in the oophorectomy group was favourable compared with the historical control group who did not undergo oophorectomy (20.8 vs 10.9 months) [4] .
Currently, the landscape for management of peritoneal disease in colorectal cancer is evolving. CRS and concomitant HIPEC (CRS-HIPEC) for KT from gastric origin has been shown to confer a survival advantage compared to CRS alone; however, this benefit was not seen in the subgroup with ovarian metastasis in the absence of peritoneal disease [11] . For ovarian metastases from colorectal origin, a recent series of 75 patients underwent CRS-HIPEC with a median overall survival of 40 months [12] . However, 19% in this group had KT alone without peritoneal disease and this group had a significantly higher three-year survival compared to those with peritoneal disease (77% versus 48%). There is at present insufficient evidence for routine HIPEC for KT, especially where there is minimal or no overt peritoneal disease, and any potential oncologic benefit must be weighed against the additional morbidity of CRS-HIPEC.
Conclusion
KTs from colorectal origin can often be rapidly progressive despite systemic chemotherapy and present with concomitant peritoneal metastatic disease, as this case demonstrates. Surgery for KTs aims to alleviate symptoms but also can result in survival benefit. The emerging utility of combined cytoreductive surgery and intraperitoneal chemotherapy for KTs suggests that KTs may be a surrogate marker for occult or future peritoneal metastasis.
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